Anti-seizure activity of African medicinal plants: The identification of bioactive alkaloids from the stem bark of *Rauvolfia caffra* using an *in vivo* zebrafish model

Talent Chipiti\(^a\), Alvaro M. Viljoen\(^a,b\), Maria L. Cordero-Maldonado\(^c\), Clinton G.L. Veale\(^f\), Fanie R. Van Heerden\(^f\), Maxlene Sandasi\(^a\), Weiyang Chen\(^a\), Alexander D. Crawford\(^c,d,e\), Gill M. Enslin\(^a,*\)

\(^a\) Department of Pharmaceutical Sciences, Tshwane University of Technology, Pretoria, 0001, South Africa  
\(^b\) SAMRC Herbal Drugs Research Unit, Tshwane University of Technology, Pretoria, 0001, South Africa  
\(^c\) Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, 4362, Luxembourg  
\(^d\) Department of Preclinical Sciences and Pathology, Norwegian University of Life Sciences, Oslo, Norway  
\(^e\) Institute for Orphan Drug Discovery, Bremer Innovations- und Technologiezentrum, Bremen, Germany  
\(^f\) School of Chemistry and Physics, Pietermaritzburg Campus, University of KwaZulu-Natal, Scottsville, 3209, South Africa

**ARTICLE INFO**

**Keywords:** Zebrafish  
*Rauvolfia caffra*  
Epilepsy  
Pleiocarpamine  
Rauverine H

**ABSTRACT**

**Ethnopharmacological relevance:** Epilepsy is one of the major chronic diseases that does not have a cure to date. Adverse drug reactions have been reported from the use of available anti-epileptic drugs (AEDs) which are also effective in only two-thirds of the patients. Accordingly, the identification of scaffolds with promising anti-seizure activity remains an important first step towards the development of new anti-epileptic therapies, with improved efficacy and reduced adverse effects. Herbal medicines are widely used in developing countries, including in the treatment of epilepsy but with little scientific evidence to validate this use. In the search for new epilepsy treatment options, the zebrafish has emerged as a chemoconvulsant-based model for epilepsy, mainly because of the many advantages that zebrafish larvae offer making them highly suitable for high-throughput drug screening.

**Aim of the study:** In this study, 20 medicinal plants traditionally used in South Africa to treat epilepsy were screened for anti-epileptic activity using a zebrafish larval model.

**Materials and methods:** Toxicity triaging was conducted on 120 crude extracts, 44 fractions and three isolated compounds to determine the maximum tolerated concentration (MTC) of each extract, fraction or compound. MTC values were used to guide the concentration range selection in bioactivity studies. The effectiveness of crude extracts, fractions and isolated compounds from *Rauvolfia caffra* Sond. in suppression of pentylenetetrazole (PTZ) induced seizure-like behaviour in a 6-dpf zebrafish larval model was measured using the PTZ assay.

**Results:** Following a preliminary toxicity triage and bioactivity screen of crude extracts from 20 African plants used traditionally for the treatment of epilepsy, the methanolic extract of *Rauvolfia caffra* Sond. was identified as the most promising at suppressing PTZ induced seizure-like behaviour in a zebrafish larval model. Subsequent bioactivity-guided fractionation and spectroscopic structural elucidation resulted in the isolation and identification of two tryptoline derivatives; a previously unreported alkaloid to which we assigned the trivial name rauverine H (1) and the known alkaloid pleiocarpamine (2). Pleiocarpamine was found to reduce PTZ-induced seizures in a dose-dependent manner.

**Conclusions:** Accordingly, pleiocarpamine represents a promising scaffold for the development of new anti-seizure therapeutic compounds. Furthermore, the results of this study provide preliminary evidence to support the traditional use of *Rauvolfia caffra* Sond. in the treatment and management of epilepsy. These findings warrant further studies on the anti-epileptic potential of *Rauvolfia caffra* Sond. using other models.

---

**Abbreviations:** CNS, central nervous system; DBE, double bond equivalent; MTC, maximum tolerated concentration; PTZ, pentylenetetrazole.

* Corresponding author.  
E-mail address: enslingm@tut.ac.za (G.M. Enslin).

https://doi.org/10.1016/j.jep.2021.114282

Received 11 April 2021; Received in revised form 15 May 2021; Accepted 30 May 2021  
Available online 10 June 2021  
0378-8741/© 2021 Elsevier B.V. All rights reserved.
1. Introduction

Epilepsy, a debilitating central nervous system (CNS) disorder, has a disproportionately high prevalence amongst people living in low- and middle-income regions. Epilepsy currently afflicts approximately 1% of the global population with almost 80% of these found in developing countries (Fricke-Galindo et al., 2018; Owolabi et al., 2020; Hacke et al., 2021). The economic implications of epilepsy are significant, this disorder is ranked the fourth largest cause of global disease burden (Zuberi and Symonds, 2015), indicating the extent of the burden that epilepsy places on healthcare systems globally.

Despite a variety of current treatment options, epilepsy remains uncontrolled in roughly one-third of patients, as well as being associated with numerous adverse drug reactions including amnesia, joint or muscle pain, tremors, and depression (Fricke-Galindo et al., 2018; Cunliffe, 2016; Kowski, 2016; Schmidt, 2009). These adverse reactions have a detrimental effect on the individual’s quality-of-life and discourage treatment adherence, with up to 25% of patients discontinuing treatment, with a concomitant burden on the economy due to inadequate control of the disease (Singh and Trevick, 2016).

Accordingly, the identification of scaffolds with promising anti-seizure activity remains an important first step toward the development of new anti-epileptic therapies, with improved efficacy and reduced adverse effects.

Although plants and plant-derived products have been utilized by mankind throughout history as a source of medicine, many of the most widely used medicinal plants have not yet been investigated comprehensively to ascertain their bioactivity and possible toxicity (Schachter, 2009). Traditional remedies for the treatment of epilepsy are still commonly used in many regions of the world including Africa (Auditeau et al., 2019), and therefore offer a potential source treasure for the identification of new hit anti-seizure compounds. The combination of modern-day techniques, models and traditional knowledge are potentially valuable in the rapid detection and isolation of bioactive components from crude plant extracts (CRBA, 2010; Galstyan et al., 2021). The economic implications of epilepsy are significant, this disorder is ranked the fourth largest cause of global disease burden (Zuberi and Symonds, 2015), indicating the extent of the burden that epilepsy places on healthcare systems globally.

Given their close physiological and genetic homology to humans, in addition to their broad range of disease associated phenotypes, zebrafish (Danio rerio) models are proving increasingly useful disease surrogates in early drug discovery (MacRae and Peterson., 2015). Furthermore, the ease with which zebrafish can be bred, monitored and manipulated, make them eminently suitable for high-throughput drug screening (Wiley et al., 2017) and bioactivity-guided natural product discovery (Crawford et al., 2008). Zebrafish larvae, exposed to chemoconvulsants such as the GABA_A antagonist pentylentetrazole (PTZ), experience acute seizure-like behaviour which mimics the changes in brain electrophysiology observed in rodent seizure models. Furthermore, marked behavioural changes, observed in humans with epilepsy, such as convulsive seizures, are replicated in phenotypic changes in zebrafish behaviour, including quantifiable changes in locomotor activity. The ictal and interictal-like epileptiform discharge recordings from the larval optic tectum and the upregulation of c-fos expression that is observed in CNS structures of zebrafish larvae are evidence of the suitability of this model. Marked behavioural changes, often accompanied by varying degrees of loss of consciousness and severe locomotor convulsions, are observed in humans during an epileptic seizure. Accordingly, zebrafish assays represent important validated models of epilepsy, which can be exploited to for the microscale in vivo bioactivity-guided isolation of new natural product compounds with anti-seizure activity potential (Cunliffe, 2015; Challal et al., 2014; Tiraboschi et al., 2020). The objective of this study was to screen South African medicinal plants used traditionally to manage epilepsy for bioactivity using a zebrafish (Danio rerio) larvae model in combination with chromatographic and spectroscopic techniques for the isolation and structural elucidation of potentially bioactive compounds. A survey of 20 African medicinal plants, selected based on their reported traditional use (Table 1) was conducted.

Table 1

| Botanical name | Plant family | Plant part(s) used | Reported traditional use | Reference |
|----------------|--------------|-------------------|--------------------------|-----------|
| Apfelia africana Sm. | Fabaceae | Roots | Convulsions | Kinsou et al. (2019) |
| Aframomum melegueta K. Schum. | Zingiberaceae | Whole stem | Epilepsy | Umukoro & Ashorobi (2005) |
| Annona senegalensis Pers. | Annonaceae | Stem bark | Epilepsy | Okeye et al. (2013) |
| Anchomanes difformis (Bl.) Engl. | Araceae | Calyx | Epilepsy | Bello et al. (2019) |
| Bacopa monnieri (L.) Pennell | Plantaginaceae | Aerial parts, stem | Epilepsy | Mathew et al. (2010) |
| Bersama lucens (Hochst.) Szszyt. | Melianthaceae | Leaves | Epilepsy | Bosch (2008) |
| Costus eger Ker Gawl. | Costaceae | Whole plant | Epilepsy | |
| Dioscorea dregena (Kunth) T. Durand & Schinz. | Dioscoreaceae | Stem bark and roots | CNS ailments including epilepsy | Methgeynoe et al. (2013) |
| Elephanthorhiza elephantina (Burch.) Skeels. | Fabaceae | Aerial parts and roots | CNS ailments | Personal communication at Faraday Herbal Market |
| Garcinia kola Hecke.| Clusiaceae | Fruits | Epilepsy | Owoye et al. (2015) |
| Hibiscus sabdariffa | Malvaceae | Seeds | Epilepsy | Kulkarni et al. (2011) |
| Landolphia owariensis | Apocynaceae | Leaves | Convulsions and epilepsy | Burkill (1985) |
| Leonotis leonurus (L.) R.Br. | Lamiaceae | Tubers | Epilepsy and seizures | Bienvenu et al. (2002) |
| Mondia whitei (Hook.f.) Skeels | Apocynaceae | Stem bark | Epilepsy | Lamidi & Bourbou (2010) |
| Morphanthus flabellifolius Welw. | Morphanthaceae | Tubers | Epileptic seizures | Personal communication at Faraday Herbal Market |
| Rauwolfia caffra Sond. | Apocynaceae | Seeds | Epilepsy | Mollel et al. (2007),b |
| Rauwolfia vomitoria Ait. | Apocynaceae | Aerial parts | Epilepsy | Olatokunboh et al. (2009) |
| Synaptotropia kirkii Oliv. | Thymelaeaceae | Roots | CNS ailments | Personal communication at Faraday Herbal Market |
| Withania somnifera (L.) Dunal. | Solanaceae | Roots | Epilepsy | Kulkarni et al. (1993) |
| Xylepis aethiopica (Dunal) A. | Annonaceae | Stem bark | Seizures | |

Zebrafish larvae are evidence of the suitability of this model. Marked behavioural changes, often accompanied by varying degrees of loss of consciousness and severe locomotor convulsions, are observed in humans during an epileptic seizure. Accordingly, zebrafish assays represent important validated models of epilepsy, which can be exploited to for the microscale in vivo bioactivity-guided isolation of new natural product compounds with anti-seizure activity potential (Cunliffe, 2015; Challal et al., 2014; Tiraboschi et al., 2020).
behaviour in an apparently dose-dependent manner, thus representing an important hit compound for the development of new therapies for epilepsy.

2. Materials and methods

The order of experimental workflow from plant species selection, MTC determination and PTZ assay for potential anticonvulsant activity on extracts and isolates, through to active compound identification in Ravuolfia caffra is presented schematically in the supplementary information (Figure S1).

2.1. Chemicals and reagents

In this study, all chemicals, reagents and solvents used for extraction were of analytical reagent grade (AR), all liquid chromatographic solvents and buffers were of HPLC grade. The purity levels of the antiepileptic drugs used as controls were valproic acid, 98%, and diazepam, ≥98%.

2.2. Selection of plant species

Various electronic databases, such as Scopus and Science Direct, and the African Herbal Pharmacopoeia (Brendler et al., 2010) were consulted to identify plants used in traditional medicine for the treatment and management of epilepsy and related conditions. The following terms were used in the literature search: epilepsy + seizure + fits + African medicinal plants. A total of 20 African medicinal plants were selected for further study, based on their reported traditional use, but lack of supporting evidence in literature to confirm this use. The plant material (Table 1), which included aerial parts (flowers, buds and twigs, leaves, stem, stem bark) and roots were sourced from Faraday market Johannesburg, South Africa and Parceval Pharmaceuticals (Pty) Ltd, Wellington, South Africa. The material was identified by A Viljoen (botanist) but for authentication of the species, the plant material was subjected to DNA bar coding. Voucher specimens and retention samples are retained in the Department of Pharmaceutical Sciences at the Tshwane University of Technology, Pretoria, South Africa.

2.3. Preparation of plant extracts

Plant material was dried in an oven at 50 °C, then ground in a Retsch BB 400 mill (Retsch Laboratories, South Africa). Six solvents of different polarities (distilled water, methanol, acetone, dichloromethane, ethyl acetate and hexane) were used to prepare extracts using 5 g of each of the relevant powdered plant parts and 50 mL of solvent. The extraction process was facilitated by sonication each sample for 30 min (Ultrasonic Sonicator, United Scientific, South Africa), each new solvent extraction was carried out using a new sample of plant material. After filtering the extracts through Whatman® filter paper (No. 1), the filtrates were concentrated under reduced pressure using a rotary evaporator (Buchi II Rotavapor™ Labotec, South Africa) at 40 °C. Nonpolar organic filtrates were concentrated using a GeneVac™ centrifugal evaporator (SP Scientific, South Africa), and aqueous filtrates concentrated by freeze drying in an AdVantage™ 2.0 benchtop freeze dryer (SP Scientific, South Africa). The dried extracts were weighed and transferred to airtight Eppendorf® microtubes (Labotec, South Africa) and stored at 4 °C. All solvents and mobile phase constituents, hexane, dichloromethane, ethyl acetate, acetone, methanol, acetonitrile and ammonia were of analytical reagent grade.

2.4. DNA barcoding

A verification study was performed to determine the identity of 20 samples to species level, where possible, using DNA barcoding, at the African Centre for DNA Barcoding (ACDB), Department of Botany and Plant Biotechnology, University of Johannesburg, South Africa. Total genomic DNA was extracted from plant material using Nucleospin® PLANT II Tissue Kits (Macherey-Nagel, Bethlehem, PA, USA) as per the manufacturer’s specifications. Polymerase chain reaction (PCR) amplification for the rbcLa and matK regions, the two officially accepted barcoding loci in this taxonomic tool, was performed in 25 μL reactions in a Gene Amp® PCR System 9700 (Waltham, Massachusetts, USA) thermocycler. The primer pairs used for amplification are listed in Table 2.

Each of the PCR reactions contained 12.5 μL of Applied Biosystems’s DreamTaq polymerase, 1.0 μL of bovine serum albumin, 0.3 μL of both forward and reverse primers, 0.5 μL MgCl2 and 9.6 μL biology grade water. PCR products were visualized on 1.5% agarose gel. A negative control was included in all experiments to ensure that no exogenous DNA was introduced into the PCR reactions. PCR products were purified using ExoSAP-IT (Thermofisher Scientific) and incubated at 37 °C for 15 min, followed by 15 min at 80 °C to remove any unincorporated primers and deoxyribonucleotide triphosphates.

Cycle sequencing reactions were executed using the BigDye® Terminator V3.1 kit (Thermofisher Scientific). Cycle sequencing products were precipitated in ethanol and sodium acetate to remove any excess dye terminator before being sequenced on an ABI 3130 × 1 genetic analyser. Sequence trace files (ABI) were imported into the bioinformatics software Geneious R (v10.2.6, Biomatters Ltd.). Bidirectional sequences were trimmed and assembled into contigs using the de novo assemble function, the Geneious assembler and the highest percentage match was reported, however, only matches of 98% or greater were considered accurate.

2.5. Zebrafish larvae bioassays

2.5.1. Ethics statement

In this project, all work using zebrafish was performed at the Zebrafish Core Facility in the Luxembourg Centre for Systems Biomedicine. This Facility is registered as an authorized breeder, supplier and

Table 2

| Region/Primer Name | Direction | Primer Sequence | Reference |
|-------------------|-----------|-----------------|-----------|
| rbcLa             | Forward   | ATGGCACCACCAAAACAGACTAAAGG | Levin et al. (2003) |
| rbcLa-F           | Reverse   | GTCATACTGACTTTTGTGTTTACGAG  | Hollingsworth et al. (2009) |
| rbcLa-R           | Reverse   | GTAAAATCAAGTCCACCG  | Hollingsworth et al. (2009) |
| matK              | Forward   | GTACAGTACTTTTGTGTTTACGAG | Hollingsworth et al. (2009) |
| matK-KIM_3F       | Reverse   | AATAACAAATACCAATCC | Hollingsworth et al. (2009) |
| matK-KIM_1R       | Reverse   | AATAACAAATACCAATCC | Hollingsworth et al. (2009) |
user of zebrafish with Grand-Ducal decree of January 20, 2016. All practices involving zebrafish were performed in accordance with European laws, guidelines and policies for animal experimentation, housing and care (European Directive, 2010/63/EU on the protection of animals used for scientific purposes), and follows the principles of the Three R’s – to reduce, replace and refine the use of animals used in scientific research. In addition, the experimental procedures performed in the present study were authorized with number LUPA 2019/87.

2.5.2. Animal husbandry

Adult zebrafish (Danio rerio) aged ≥ 3 months) stocks of the AB wild type strain were maintained at 28.5 °C, on a 14/10-h light/dark cycle under standard aquaculture conditions (Westerfield, 2000). The male to female ratio was maintained at approximately 50:50, for breeding, the ratios ranged from 2:1 to 3:2, female to male respectively, in mating cages. Embryos were obtained by natural spawning and after collection and sorting, fertilized embryos were reared in 0.3X Danieau’s medium (17.4 mM NaCl, 2 mM KCl, 0.12 mM MgSO4, 1.8 mM Ca(NO3)2, 1.5 mM HEPES pH 7.6 and 1.2 µmethylene blue) at 28 °C (±0.5 °C). Medium exchange was carried out daily to ensure the viability of the larvae for the assays, until 6-dpf.

2.5.3. Preparation of stock and test solutions

Stock solutions of the required concentrations (ranging from 10 µg/mL to 1000 µg/mL) of the crude extracts, fractions and pure compounds were prepared using either 100% DMSO (Sigma-Aldrich, St. Louis, MO, USA; AR grade) or ultrapure water (Milli-Q, Merck), depending on their solubility, and were stored at –20 °C until needed. Valproic acid (VPA) (Sigma-Aldrich, Belgium) and diazepam (DZP) (Sigma-Aldrich, Belgium) were used as standard anti-epileptic drugs (AEDs). Stock solutions of valproic acid, 200 mM, were prepared in ultrapure water, and of diazepam, 10 mM, in 100% DMSO. From these stock solutions, all corresponding test solutions were then freshly prepared on the day of the experiment in the vehicle (Veh, 0.3X Danieau’s medium with 1% DMSO). For the anticonvulsant bioassay, a stock solution of 40 mM PTZ (Sigma-Aldrich, Belgium) was freshly prepared prior each experiment in 0.3X Danieau’s medium.

2.5.4. Toxicological evaluation and determination of maximum tolerated concentration (MTC)

Prior to all in vivo assays, the maximum tolerated concentration (MTC) was determined for all crude extracts (Table S1, supplementary data), fractions and isolated compounds, in order to establish the range of safe concentrations for use in the PTZ bioassays. Guidelines described by Afrikanova et al. (2013), were followed, with slight modifications. Zebrafish larvae, 6-dpf (at this stage male to female ratio was unknown since it is difficult to differentiate between the sexes at this early larval age), were incubated in 48-well microplates (five larvae per well) with either 500 µL of Veh, 1 mM VPA or 16 µM diazepam as the AED positive control, or the test groups comprising plant extracts, fractions or isolated pure compounds at concentrations ranging from 10 µg/mL to 1000 µg/mL. Immediately after exposure each well was visually assessed under a stereo microscope (Olympus SXZ10, Belgium) for any signs of acute locomotor impairment and any abnormal larvae were removed. The plate was then covered with aluminium foil, to create an environment of complete darkness and incubated for 18 h at 28.5 °C. At the end of the incubation period the assessment of the larvae was repeated. The following were considered signs of acute locomotor impairment: hypoactivity, decreased or no touch/escape response upon a light touch of the tail with a fine needle, loss of posture, body deformation, exophthalmos, slow or absent heartbeat, and ultimately death. A larva was considered normal if it could travel a distance equivalent to twice its body length. A shorter distance travelled, or movement in the same place, was scored as a decreased or impaired touch response. No visible movement upon a touch stimulus was counted as a no response. The MTC was considered to be the maximum concentration of the test solution that did not cause death or toxicity in more than two out of five larvae in a well after the 18 h incubation period. All toxicity tests were conducted in triplicate and MTCs of extracts, fractions or pure compounds were considered acceptable for further testing and were evaluated for anticonvulsant activity using the PTZ assay.

2.5.5. Evaluation of anticonvulsant activity: pentylenetetrazole (PTZ) assay

The anticonvulsant activity assay was conducted using the method described by Afrikanova et al. (2013), with minor modifications. The locomotor activity of zebrafish larvae was tracked and recorded over two 30-min periods, using a specialized high-resolution video camera tracking system (DanioVision,™ Noldus, Wageningen, The Netherlands), after incubation in test and control solutions and again after exposure to the convulsant drug, PTZ (Fig. 1, Video clip, SV1 in supplementary data).

Six-dpf larvae were pre-incubated in 96-well microplates (one larva per well with 100 µL of 1 mM VPA or 16 µM diazepam as the positive control, crude extracts, fractions or pure compounds (at a range of concentrations below or equal to MTC values) or Veh as the negative control, for 18 h at 28.5 °C in complete darkness. Five larvae per extract/fraction/compound were used per experiment for the initial screening, which was increased to ten for the subsequent concentration response studies of extracts with potential bioactivity. All experiments were conducted in triplicate. Following the 18 h pre-incubation, video tracking of locomotor activity was conducted for 30 min in the dark. After this period, video tracking was suspended, and 100 µL of 40 mM PTZ was added to each well, except in the negative control, resulting in an effective final concentration of 20 mM PTZ per well. For the negative control 100 µL of 0.3X Danieau’s medium 0.3X (100 µL) was added to each corresponding well. After addition of PTZ, larvae were allowed to habituate for 5 min in the dark chamber of the automated tracking device. After this, video tracking was resumed for a further 30 min. The total locomotor activity was then quantified (EthoVision™ XT, Noldus, Wageningen, The Netherlands) and total distance moved expressed in mm.

2.6. Chemical profiling, isolation and structural elucidation of bioactive compounds

The chromatographic chemical profiling of extracts found to be potentially active in the PTZ bioassay, the subsequent fractionation, isolation and structural elucidation of the active compounds is described in this section.

2.6.1. Preparative ultra-performance liquid chromatography mass spectrometry (UPLC-MS) analysis

Fractionation of the crude plant extracts and isolation of bioactive compounds was performed on a Waters AutoPurification™ chromatographic system fitted with a Waters photodiode array (2998 PDA)
extracts were prepared for injection at a concentration of 50 mg/mL in methanol and filtered (0.22 μm; Millipore®). Injection volumes ranged from 100 to 300 μL. The chromatographic conditions were optimised to achieve good separation of the sample constituents. Separation was achieved on an XBridge™ Preparative C18 column (19 × 250 mm, i. d., 5 μm particle size, Waters) maintained at 40 °C. The mobile phase consisted of 0.1% ammonium hydroxide (Solvent A) and acetonitrile (Solvent B; ultra-gradient grade; Romil, Cambridge, England), at a flow rate of 20 mL/min. Gradient elution was applied as follows: Initial ratio 90% A:10% B, maintained for 1 min, changed to 55% A:45% B over 4 min, changed to 15% A:85% B within 7 min, to 5% A:95% B within 0.5 min and returning to the initial ratio within 0.5 min. The total run time was 13 min.

The preparative HPLC system was interfaced with an Acquity™ QDaTM mass detector (Waters, Milford, MA, USA), positive ionization mode. The probe temperature was set at 600 °C and source temperature at 120 °C. The capillary and cone voltages were set to 800 and 10 V, respectively. Data were collected between m/z 100 and 650 using MassLynx™ 4.1 (Waters, USA) software. Fractions were obtained by collecting 1-min aliquots of the eluent from the active crude extracts into test tubes arranged in collection trays. The target compounds were collected from various runs, and subsequently combined to obtain a sufficiently large volume of each fraction, and analysed by ultra-performance liquid chromatography-mass spectrometry (UPLC-MS).

2.6.2. UPLC-MS analysis
A Waters UPLC-MS system was used for analysis of all crude extracts, fractions and isolated compounds. The system was fitted with a Waters PDA detector (Milford, Massachusetts (MA), USA). A 1 μL volume of each sample (1 mg/mL in methanol) was analysed. Separation was accomplished using an Acquity™ UPLC BEH C18 column (150 mm × 2.1 mm i. d., 1.7 μm particle size). The mobile phase consisted of 0.1% ammonium hydroxide (Solvent A, Xevo grade) and acetonitrile (Solvent B; ultra-gradient grade; Romil, Cambridge, England), at a flow rate of 0.3 mL/min. Gradient elution was applied as follows: Initial ratio 95% A:5% B, changed to 80% A:20% B over 3 min, changed to 50% A:50% B within 7 min, to 45% A:55% B within 1 min, to 5% A:95% B within 2 min, keeping for 1 min and returning to the initial ratio within 0.5 min. The total run time was 16 min.

The UPLC-MS system was interfaced with a Xevo™ G2 Quadrupole Time-of-Flight mass spectrometer (qToF-MS) (Waters, USA). The mass spectrum was obtained in positive electrospray ionization mode, as this yielded better sensitivity. Nitrogen at a flow rate of 500 L/h was used as the desolvation gas, with desolvation temperature set to 350 °C. A source temperature of 100 °C was maintained. The capillary and sampling cone voltages were set to 3000 and 38 V, respectively. Data were collected between m/z 100 and 1500 and processed by Masslynx™ 4.1 chromatographic software.

2.6.3. Nuclear magnetic resonance spectroscopy analysis
Proton (1H) (500 MHz) and carbon-13 (13C) NMR (125 MHz), correlation spectroscopy (COSY), heteronuclear single quantum coherence (HSQC) and heteronuclear multiple bond correlation (HMBC) spectra were recorded on a Bruker AvanceTM III 500 spectrometer. All proton and carbon chemical shifts are quoted relative to the relevant residual solvent signal (MeOD: 1H, 3.31 ppm, 13C, 49.00 ppm). Coupling constants are reported in Hz. All experiments were conducted at 30 °C unless specified otherwise.

2.6.4. Data analysis
Locomotor behaviour data were first normalized against the Veh + PTZ controls from the same tracking experiment, and the normalized data from replicate tracking runs were subsequently pooled. Antiepileptic drug plus pentylentetrazazole (AED + PTZ) treatment and Test (crude extracts, fractions and compounds) + PTZ groups were compared to Veh + PTZ groups using repeated measures (mixed model) ANOVA. Both electrophoretic parameters and the average total movement over the 30 min period were compared using Student’s T-test one-way ANOVA, followed by Dunn’s multiple comparison test using Graph Pad 7 Prism™ software (GraphPad Software, San Diego, USA). Differences with P < 0.05 were considered significant.

3. Results and Discussion

3.1. Identification and verification of the identity of selected plant species

Species identification was confirmed by the African Centre for DNA barcoding at the University of Johannesburg, South Africa. A total of 15 plants, where able to be identified to species level with a high confidence level. Three plants were identified to genus level and two plant species, Landolphia owiowariensis and Xylopia aethiopica, could not be identified due to lack of reference standards in the database. Where two possible species were indicated from the DNA library, the geographic distribution map for the species used as an aid to correct identification, as was the case for Rauwolfia verticillata/Rauwolfia caffra assigned as Rauwolfia caffra due geographical distribution matching. The majority of the plant species identities was assigned to species level, confirming that the vernacular names used by traditional healers and herbalists are accurate. This also underlines the value of complementary techniques such as DNA barcoding in correctly identifying medicinal plants, and where possible (as in this study) an independent, non-affiliated laboratory should be used.

The responsible development of governance compliant medicinal products mandates obtaining valid scientific evidence on the quality, efficacy and safety of medicinal plants. This includes ascertaining the toxicity profile prior to any bioactivity testing. In the current study the MTC values yielded valuable information on concentration determination for each sample of herbal extract that did not compromise the normal survival of the zebrafish larvae in bioassays (Gad, 2014).

This section provides details of the results obtained during toxicity studies performed on crude vehicle and the standard AEDs used in the study and the assessment of the effect of crude plant extracts on the locomotor activity of zebrafish larvae using the PTZ assay.

3.1.1. Maximum tolerated concentrations (MTCs)
Fifty of the 120 crude extracts tested (Table S1, supplementary data) proved toxic to the larvae at the lowest concentration, 10 μg/mL. The MTCs of the remaining 70 extracts ranged from 10 μg/mL to nontoxic at the highest concentration tested, 1000 μg/mL. The highest MTC values recorded were, for the majority of the plants, those from the aqueous extracts. It was also determined that as the polarity of the extraction solvent decreased, the MTC value of the extract decreased. Aqueous extracts were consequently found to be tolerated by larvae at higher concentrations than more non-polar extracts. The MTC values were determined for 18 out of a total of 20 crude extracts.

The Xylopia aethiopica and Bersama lucens aqueous extracts were toxic at all the concentrations tested; for these extracts more than three larvae out of five in a well died due to toxicity and in many cases all larvae died, indicative of the severity of the toxicity of the extracts.

The ethyl acetate extracts found to be the most toxic, with 11 out of 20 extracts found to be toxic over the full concentration range tested. This observation can be explained by two potential contributing factors: first, it is well documented that the more toxic secondary metabolites are found in the non-polar extracts and second, while every effort was made to evaporate all solvent residue from extracts, some residue of the toxic ethyl acetate may have remained trapped in the extract matrix, with a concomitant toxic effect. Many studies in which the effects of various plant extracts have been studied, it has been reported that, most notably, that the water extracts are less toxic compared to the organic solvent extracts (Boukandou et al., 2015; Ferreira- Machado et al., 2004). It is feasible that the most toxic principles
of the plants (e.g. alkaloids, tannins) were found in non-polar extracts of the plants in the current study. Aqueous extracts proved to be less toxic to the larvae than extracts from non-polar solvents: It was noted that as the polarity of the extraction solvent decreased, the MTC also decreased. The findings from the current study with respect to anti-epileptic herbal medicines are in agreement with this observation.

These findings are encouraging contributory evidence for safety, given that traditional medicinal preparations are usually aqueous extracts administered in the form of decoctions and teas. It is fortuitous that fewer toxic principles are obtained by using water, the universal
non-toxic neutral solvent, in contrast to extraction with organic solvents, which are known to be toxic, often directly proportional to concentration, yielding an extract matrix of toxic compounds. Maximum tolerated concentrations were determined for all fractions of the crude extracts, with the highest MTC value of 500 μg/mL recorded in the methanolic (fractions 7–12) and aqueous (fractions 15–19, 21, 24) fractions of *Rauvolfia caffra*. The lowest tolerated concentration as determined in the MTC study was 10 μg/mL for aqueous fraction 25 of *Rauvolfia caffra*. *Withania somnifera* displayed higher toxicity in the larvae, with the highest MTC of 500 μg/mL recorded for only two methanolic fractions, fractions 30 and 31. Ten *Withania somnifera* methanolic fractions were too toxic, even at the lowest concentration applied, 10 μg/mL, for any MTC to be determined. The general toxicity profile of fractions was found to be similar to that of the crude extracts.

Two compounds, denoted as m/z 323 and m/z 325 were isolated from *Rauvolfia caffra* methanolic extracts, and their MTC values determined. Compound m/z 323 was recorded as having an MTC value of 200 μg/mL, while compound m/z 325 had a MTC value of 400 μg/mL. The toxicity profile of compound m/z 323, the most bioactive compound with respect to locomotor activity reduction, offers a wide range of concentrations suitable for future concentration-response studies.

### 3.1.2. Bio-activity guided fractionation

Of the 70 extracts assessed for locomotor inhibitory activity, six extracts exhibited an apparently concentration-dependent reduction in the seizure-like behaviour of larvae after treatment with PTZ (Fig. 2). The crude extract with the highest activity was the aqueous extract of *Rauvolfia caffra* (Fig. 2 A and B). An apparent concentration-dependent anti-seizure activity, indicative of an increase in bioactivity, was observed compared to negative control, from 50 μg/mL to the highest concentration tested, 350 μg/mL. Statistical significance (P < 0.001) was observed for extracts concentrations 200 μg/mL, 300 μg/mL and 350 μg/mL (Fig. 2A). A similar apparent concentration-dependent effect was also observed for the methanolic extract of *Rauvolfia caffra* (Fig. 2 B), with a highly statistically significant difference exhibited for crude extract concentrations 300 μg/mL (P < 0.001), 400 μg/mL and 500 μg/mL (both P < 0.0001).

*Withania somnifera*, methanolic (Fig. 2 C) extract also displayed a concentration-dependent effect in the PTZ test, with a highly statistically significant difference between negative control and extracts at 250 μg/mL (P < 0.001), 300 μg/mL (P < 0.0001) and 400 μg/mL (P < 0.0001). At concentrations of 100 μg/mL and 200 μg/mL there was no significant difference between control and crude extract.

*Rauvolfia vomitoria*, *Annona senegalensis* and *Costus afer* (Fig. 2D–F) crude extracts exhibited statistically significant effect in the PTZ test in extract concentrations from 100 μg/mL, 150 μg/mL and 200 μg/mL (P < 0.01 for all three plants), respectively.

While all six extracts showed promising activity, given their marginally superior activity, the methanolic extracts of *R. caffra* and *Withania somnifera* were selected for further investigation. In the PTZ assay no significant effect was observed after treatment with the aerial parts of the following plants *Afzelia africana*, *Anchomanes diformis*, *Aframomum melegueta*, *Bersama lucens*, *Dioscorea dregemana*, *Elephantorrhiza elephantina*, *Garcinia kola*, *Hibiscus sabdariffa*, *Landolphia owariensis*, *Leonotis leonurus*, *Mondia whitei*, *Synaptolopsis kirkii*, *Withania somnifera*. In *Xylopia aethiopica* no bioactivity assays were conducted because of the high toxicity of the plant, which precluded determination of the MTC even at a concentration as low as 10 μg/mL. Interestingly, increased pro-convulsant activity was recorded with *Afzelia africana* (ethyl acetate extract) and *Anchomanes diformis* (aqueous extract), where locomotor activity, after the induction of seizures by PTZ, was further increased, suggesting that these plant extracts possibly exacerbate the seizure severity.

### 3.2. Assessment of the anticonvulsant activity of fractions and isolated compounds

#### 3.2.1. Maximum tolerated concentration (MTC) of fractions

The fractionation of *Rauvolfia caffra* and *Withania somnifera* extracts into 1-min aliquots using prep-HPLC yielded 44 fractions. The MTC values for all 25 fractions from *Rauvolfia caffra* were determined. The lowest fraction MTC values were for *Rauvolfia caffra*, aqueous and methanolic fractions, recorded at 10 μg/mL and the highest recorded 500 μg/mL. For *Withania somnifera* MTC values could be determined for only nine of the 19 fractions. The remaining ten were highly toxic over the concentration range tested. It was also observed that in the majority of the *Withania somnifera* fractions the MTC values were relatively low compared to those of *Rauvolfia caffra*, indicative of potentially higher toxicity for *Withania somnifera*. No trend was recorded in the MTC values between water and methanolic fractions, with potential toxicity thus similar to that of the crude extracts.

#### 3.2.2. Inhibition of seizure-like behaviour by *Rauvolfia caffra* and *Withania somnifera* fractions: pentylentetrazole (PTZ) assay in 6-dpf zebrafish larvae

Selected crude extracts were subjected to time-based fractionation using preparative HPLC-MS into 1-min aliquots to yield 44 fractions. The 44 non-toxic fractions from *Rauvolfia caffra* and *Withania somnifera*...
revealed five fractions (fractions 8 to 12) that displayed significant antiepileptic effect from the *Rauvolfia caffra* methanolic fraction, with fractions 10–12 in particular displaying the most significant anti-seizure activity (Fig. 3 A–C).

Neither the *Rauvolfia caffra* aqueous fractions (fractions 13–25) nor the *Withania somnifera* methanolic fractions (fractions 26–44) displayed any significant effect compared to negative control.

Fig. 3 shows the results of the PTZ assay on *Rauvolfia caffra* methanolic fractions. Three fractions, fractions 10, 11 and 12 displayed promising bioactivity, with fraction 12 active from the lowest concentration tested, 50 μg/mL (*P* < 0.01), whereas fractions 10 and 11 were potentially bioactive from a concentration of 100 μg/mL (*P* < 0.01) compared to the negative control. A statistically significant bioactive effect was observed in fractions 10, 11 and 12 at a concentration of 400 μg/mL (*P* < 0.0001).

These results indicated activity for all *Rauvolfia caffra* fractions tested and further optimally designed studies would be required for concentration-activity response confirmation.

### 3.2.3. Maximum tolerated concentration (MTC) of isolated compounds

Two compounds, *m/z* 323 and *m/z* 325 were isolated from *Rauvolfia caffra* methanolic extracts, and their MTC values determined as 200 μg/mL and 400 μg/mL, respectively.

### 3.2.4. Inhibition of seizure-like behaviour by the isolated compounds: pentylentetrazole (PTZ) assay in 6-dpf zebrafish larvae

An apparently concentration-dependent bioactivity was observed (Fig. 4, A and B) with compound *m/z* 323 (compound 2), compared to the negative control, with statistically significant activity displayed at 100 μg/mL and 200 μg/mL treatment concentrations (*P* < 0.001 and *P* < 0.0001 respectively). Compound *M/z* 325 (compound 1) did not display significant bioactivity with respect to locomotor activity reduction.

### 3.3. Chemical profiling of bioactive *Rauvolfia caffra* crude extract, fractions and compounds

The UPLC-MS profile of the bioactive methanolic crude extract of *Rauvolfia caffra* is provided in Fig. 5 and highlighted are the peaks that were targeted for isolation since these peaks were common to both the crude extract and certain fractions. Guided by this observation the common peaks were targeted for isolation, namely *m/z* 323, *m/z* 325, *m/z* 335. It was possible to successfully isolate *m/z* 323 and, *m/z* 325 to 100% purity levels, the percentage yields were 0.032% and 0.014% respectively.

Compound *m/z* 323, present in the crude extract (RT = 11.26 min) and fractions 10 to 12, was elucidated as pleiocarpamine, a known compound isolated from *Rauvolfia caffra* stem bark (Nasser and Court, 2017).
Journal of Ethnopharmacology 279 (2021) 114282

Compound m/z 325 present in the crude extract (RT = 3.66 min) and all fractions, was identified as a pentacyclic alkaloid and given the trivial name of rauverine H. A previously reported hydroxyl isomer of this compound, rauverine A (3), Fig. 6), was isolated from twigs of Rauvolfia verticillata (Lour.) Baill (Zhang et al., 2013) and a quadricyclic analogue, rauvotetraphylline A (4, Fig. 6) was earlier reported by Gao et al. (2012).

UPLC-MS data used to tentatively identify compounds isolated from Rauvolfia caffra is summarised in Table 3. Chromatograms and UV spectra confirming the purity of isolates are provided as supplementary data (S1.3–1.4).

Subsequent UPLC-MS chemical profiling was conducted in order to isolate and identify the chemical entities possibly responsible for this activity. A molecular ion at 325.1926 m/z [M+H]+ (1) was identified in the crude extract and all the active fractions, while a molecular ion at 323.1760 m/z [M+H]+ (2), which was present in the crude extract, was found in fractions 10–12. These chemical constituents were isolated from each of the appropriate fractions, where they were again subjected to toxicity and seizure-like behaviour inhibition assessment. Compounds 1 and 2 were found to have MTC values of receptivity. Furthermore, while compound 1 did not display significant activity, compound 2 was found to have a statically significant effect in the suppression of zebra-fish seizure-like activity, at concentrations well below its MTC (Fig. 4 A and B). Chromatograms confirming the purity of isolates are provided as supplementary data (spectral data1.3 and 1.4).

### 3.4. Structural elucidation of compounds isolated from Rauvolfia caffra

The interpretation of 1D and 2D NMR spectra of the two compounds, m/z 325 (compound 1) and m/z 323 (compound 2), isolated from Rauvolfia caffra stem bark methanol crude extract is provided in this section. Compounds m/z 325 (compound 1) and m/z 323 (compound 2) were identified as tryptoline derivatives, the previously unreported rauverine H (1, Fig. 6), and the known compound pleiocarpamine (2, Fig. 6). 1H and 13C assignments for compounds m/z 323 and m/z 325 are presented in Table 4. Spectra and key 1H–1H correlation spectroscopy correlation (COSY) and heteronuclear multiple-bond correlation spectroscopy (HMBC) configurations pertaining to pleiocarpamine (Figs. 6 and 7 (1)) and rauverine H (Figs. 6 and 7 (2)) are supplied as supplementary data. UPLC-MS data and NMR data are summarised in Table 4 and briefly discussed as a conclusion to this section. Chromatographs and PDA spectra are provided as supplementary data (Spectral data1.3 and 1.4).

The deconvoluted mass of the molecular ion of compound 1 (325.1926 m/z [M+H]+) corresponded to a molecular formula of C20H24N2O2 whose double bond equivalent (DBE) was calculated at 10. Inspection of the downfield region of the 1H NMR spectrum in conjunction with the HSQC spectrum revealed the presence of a broad...
singlet (δH 8.57) unassociated to a carbon atom, consistent with an indole NH, as well as three aromatic CH signals δH 7.21 (1H, d, J = 8.6 Hz), δH 6.87 (1H, d, J = 2.2 Hz) and δH 6.75 (1H, dd, J = 8.6, 2.2 Hz) whose coupling constants in addition to COSY correlations allowed us to assign an AMX system consistent with a substituted indole. All three of these proton signals correlated though HMBC with a quaternary carbon (δC 152.3), whose chemical shift, and lack of further NMR correlations was indicative of a hetero aromatic substituent. The 13C spectrum contained two quaternary carbon signals at δC 133.5 and δC 128.2, consistent with signals for C-13 and C-8 respectively for previously reported tryptoline derivatives.15,16 The aromatic proton signal at δH 7.21 was assigned to H-12 based on an HMBC correlation to the carbon signal at δC 128.2, while similarly, the positions of the proton signals at δH 6.87 (H-9) and δH 6.75 (H-11) were assigned trough corresponding HMBC correlations with the carbon signal at δC 133.5. This information in conjunction with the coupling constants of these position allowed us to unambiguously assign the putative heteroaromatic indole substituent to C-10. An HMBC correlation between H-9 and a quaternary carbon signal at δC 101.1 allowed us to assign this carbon signal to C-7. Furthermore, methylene protons at δH 3.26 (H-6a) and δH 3.02 (H-6b) and a methine proton 3.52 (H-5), which correlated to each other through COSY, both positioned δH 2.13 (H-16) and subsequently between the H-16 and a methine at δH 3.02 dd (H-6a) and a methine signal at δH 1.71 (H-18) were assigned through corresponding HMBC correlations between positions 15 and 19. A long range resonance. A key HMBC correlation between H-16 and C-14 as well as H-15 and C-3 allowed for the final assignment of these positions. A proton signal at δH 4.41 (H-19) which correlated through HSQC to a carbon resonance at δC 122.1 was consistent with an alkene residue. Furthermore, a COSY correlation between H-19 and a methyl signal δH 1.71 (H-18) indicated the presence of an ethylidene substituent. Dual HMBC correlations between H-18, H-16 with a quaternary carbon at δC 129.1 (C-20), consistent with an alkene signal, indicated the possible site of attachment of the ethylidene. This tentative assignment was supported by corresponding HMBC correlations between positions 15 and 19. A long range COSY correlation between H-19 and a diastereotopic methylene (δH 4.41, 4.19, H-21), in addition to HMBC correlations between H-15, 18 and 19 with C-21, allowed us to unambiguously assign position 21. Finally, an outstanding methylamine singlet (δH 3.08) correlated through HMBC to C-5 and C-3 respectively, allowing us to position this substituent on the bridgehead nitrogen, resulting in our proposed pentacyclic structure, with 5 double bonds, which complies with our calculated DBE. Zhang et al. have previously reported a hydroxy isomer, rauverine A (3) isolated from the twigs of R. verticillata13 while a quadra cyclic analogue, rauvetraphylline A (4), has been reported by Gao et al.17 Accordingly we assigned this compound the trivial name rauverine H, (Table 3, Fig. 7). While presumably compound 1, 3 and 4 are biosynthetically related, the relative configurations of the 4 common stereocenters as well as the E/Z configuration of the double bond of compounds 3 and 4 is not congruent. The NOESY spectrum of compound 1, showed that the protons at positions 3 and 5, both possessed strong NOE correlations with the N-methyl resonance (Fig. 8). This suggested that all three moieties orientate in same plane, allowing us to assign a cis-relationship between 3 and 5, which was in agreement with the assignment of both compounds 3 and 4. Similarly, NOE correlations between protons 15 and 16 also suggested a cis-relationship. The absence of NOE correlations between protons 5 and 16 indicated a trans-relationship between these protons. Together this data suggested that

### Table 4

| Position | δH (500 MHz) | J (Hz) | δC (125 MHz) |
|----------|--------------|--------|--------------|
| 1        | 101.1        |        | 109.7        |
| 2        | 128.2        |        | 128.6        |
| 3        | 103.5        | 7.53-7.52 | m | 1H | 119.4 |
| 4        | 152.3        | 7.09-7.06 | m | 2H | 121.1 |
| 5a       | 113.8        | 7.09-7.06 | m | 2H | 122.1 |
| 5 b      | 113.2        | 6.99-6.97 | m | 1H | 113.6 |
| 6 a      | 133.5        |        | 139.4        |
| 6 b      | 136.4,2.2,3  |        | 136.3,5      |
| 7        | 33.4         | 2.20   | ddd | 1H | 136.4,2.2,3 |
| 8        | 2.63         | dt     | 1H | 136.3,5 |
| 9        | 3.62         |        | m | 1H | 34.3 |
| 10       | 5.33         |        | d | 1H | 4.1 |
| 11       | 122.1        | 5.39   | q | 1H | 125.7 |
| 12       | 129.1        |        | 133.5        |
| 13       | 65.8         | 2.74   | d | 1H | 131.1 |
| 14a      | 131.1        | 1.87   | dt | 1H | 131.1 |
| 14 b     | 48.1         | 3.61   | s | 3H | 52.6 |
| 2         | 101.1        |        | 109.7        |
| 3        | 128.2        |        | 128.6        |
| 4        | 103.5        | 7.53-7.52 | m | 1H | 119.4 |
| 5 a      | 152.3        | 7.09-7.06 | m | 2H | 121.1 |
| 5 b      | 113.8        | 7.09-7.06 | m | 2H | 122.1 |
| 6 a      | 113.2        | 6.99-6.97 | m | 1H | 113.6 |
| 6 b      | 139.4        |        | 139.4        |
| 7        | 34.3         |        | 34.3         |
| 8        | 62.0         |        | 62.0         |
| 9        | 170.5        |        | 170.5        |
| 10       | 128.0        |        | 128.0        |
| 11       | 125.7        |        | 125.7        |
| 12       | 133.5        |        | 133.5        |
| 13       | 57.3         |        | 57.3         |
| 14a      | 131.1        | 1.87   | dt | 1H | 131.1 |
| 14 b     | 48.1         | 3.61   | s | 3H | 52.6 |

* Assigned by HSQC.

### Table 4

1H (500 MHz) and 13C (125 MHz) assignment of compounds 1 and 2 in CD3OD.
compound also featured an ethylidene substituent (δ_H 5.39, δ_C 125.7). An additional feature was the presence of a carbonyl resonance, (δ_C 170.5), which correlated through HMBC to a methyl signal, (δ_H 3.61, δ_C 52.6) indicating the presence of an ester moiety. The aromatic region featured three correlating signals, with a combined integral of four protons (δ_H 7.53–7.52, 1H; 7.09–7.05, 2H; 6.99–6.97, 1H) which were characteristic of an unsubstituted indole ring. Furthermore, HMBC correlations between H-12 and δ_C 129.6 (C-8) as well as H-9 with δ_C 139.4 (C-13) and 109.7 (C-7) were consistent with tryptoline resonances, as observed for compound 1. A diastereotopic methylene (δ_H 3.21, 2.80) correlated through HMBC to C-8 and C-7, allowing us to assign this position as H-6. Position H-5 was assigned by a COSY correlation between its diastereotopic methylene signal (δ_H 3.39, 2.38) and H-6. The H-5 resonance displayed an HMBC correlation to a carbon signal at δ_C 136.7, which we assigned as C-2, which is again a typical chemical shift for this position on the tryptoline scaffold. Furthermore, H-5 correlated with two carbon signals at δ_C 57.3 and δ_C 51.7, which were tentatively assigned as two carbons at positions 21 and 3, respectively. In turn, the methylene signals associated with position 21 (δ_H 2.74, 1.87) correlated through HMBC to C-3. A COSY correlation between H-3 (δ_H 4.05–4.04) and a diastereotopic methylene at δ_H 2.63 and 2.20 (H–14), which in turn correlated through HMBC to C-2 allowed us to assign the relative positions of these signals to the numbered positions shown. Sequential COSY correlations between H-14 and H15 (δ_H 3.62) followed by H-16 (δ_H 5.33) allowed us to assign their relative relationship. This relationship assignment was supported by HMBC correlations between H-16 and C-14 and H-15 and C-3. Both H-21 and H-16 correlated to the ethylidene attachment carbon signal (C-20) at δ_C 133.5, while a further HMBC correlation between C-21 and δ_C 5.39 (H-19) allowed us to assign the position of attachment of the ethylidene substituent. HMBC correlations between H-16 and the C-17 carbonyl as well as a methyl signal at δ_H 3.61, allowed us to place the methyl ester. Finally, an HMBC correlation between H-16 and C-2, allowed us to complete the 5th ring, and allowed us to assign compound 2 as the tetracyclic tryptoline alkaloid pleiocarpamine^{18} (Table 3, Fig. 6).

4. Summary and Conclusions

To validate the traditional use of medicinal plants for the treatment of epilepsy and related CNS disorders, adequate scientific evidence is required. In this study 20 plant species were identified from the literature for their traditional use in the treatment of various CNS conditions, including epilepsy. Toxicity assays were conducted to determine the maximum tolerated concentration in zebrafish larvae, these values were then used in the determination of concentrations to be used in subsequent bioactivity assays. Maximum tolerated concentrations varied widely amongst the plant species, ranging from 10 μg/mL to no toxic effect even at concentrations of 500 μg/mL. In 120 crude extracts, MTCs were determined for 70, with 50 extracts proving too toxic to the zebrafish larvae to establish MTC.

The PTZ assay is widely accepted as an indication of potential anticonvulsant properties of a test compound or extract (Berghmans., 2007). From a total of 20 plants tested in this study, only five plant species namely Rauvolfia caffra, Withania somnifera, Annona senegalensis, Costus afer and Rauwolfia vomitoria, showed bioactivity in the PTZ assay. The positive controls using the well-known AEDs, valproic acid (1 mM) and diazepam (16 μM) suppressed PTZ-mediated increases in larval locomotor activity, indicative of anticonvulsant activity. In six of the 70 crude extracts from the plant species showing bioactivity, activity of a possible concentration-dependent nature was observed, a finding that warrants further investigation in well-designed concentration-response studies in zebrafish larvae or another model.

Rauvolfia caffra was ultimately identified as the best potential candidate for yielding anticonvulsant compounds and after bioassay and chemical profiling of the fractionated extracts, two compounds were targeted for isolation. The two compounds were identified using various
NMR techniques; compound m/z 323 was identified as pleiocarpamine, a compound reported to have been isolated from the stem bark of *Rauvolfia caffra* Sond. (*Nasser and Court, 1984*). This compound has also been isolated from other plant species, such as from *Alstonia angustifolia* (Tan et al., 2013; Tan et al., 2014). Pleiocarpamine was reported for the first time in our study to be active against PTZ-induced seizures in zebrafish larvae. The second compound, compound m/z 325, was structurally elucidated. This compound has been assigned the trivial name rauverine H, an analogue of rauvotetraphylline A. Of these two compounds, pleiocarpamine exhibited potential anticonvulsant activity in the PTZ assay in zebrafish larvae. The most active extracts, fractions and resultant isolated pure compound were all from *Rauvolfia caffra*, one of the 20 of 80 species that belong to the Apocynaceae family that are indigenous to Africa (*Kayani, 1977*).

The work presented in this study supports the assertion of Challal et al. (2014), that a combination of modern techniques such as preparative HPLC with an in vivo model such as a zebrafish larval model, is a new strategy in rapid identification and efficient isolation of bioactive compounds from plants.

Certain limitations to this study need to be recognised, as highlighted by Afrikanova et al. (2013), locomotor activity should be used as a primary in vivo assay and follow-up assays are essential to support and confirm results. As a recommendation, the potential anticonvulsant activity shown by the compounds isolated from *Rauvolfia caffra* needs to be confirmed by electrophysiological studies and assays in different models, such as rodents. The activity shown by the isolated compound, pleiocarpamine warrants further investigation. Follow up investigations such as molecular docking to confirm the binding of the identified compound to specific receptors implicated in epileptogenesis, is highly recommended. It should be noted that plants labelled as “non-active” in this study should not be dismissed as unvalidated evidence of their traditional use. Chemotypic variation is rampant in almost all plant species and for practical purposes only a single collection of each species was screened in this study and may not be representative of potentially active chemotypes. Furthermore, although the zebrafish model has emerged as a valid first-pass screening model, with a response to AEDs with different modes of action, the technique does impose inherent limitations, such as the solubility of extracts and molecules in an aqueous environment (irrespective of the use of surfactants). Thirdly, epilepsy is a complex condition with numerous types of seizure manifestations. The plants selected for this study may exert their apparent anti-convulsant effect through various other mechanisms, or have sedative effects. As with all in vivo models adequate validation and confirmation of activity using other models is necessary. This study underlines the value of ethnobotany-guided drug discovery for the rapid identification of therapeutically active phytochemicals and provides scientific evidence to support the use of *Rauvolfia caffra* as an anti-epileptic traditional medicine. It also highlights the potential of the zebrafish PTZ assay in rapidly identifying bioactive small compounds of natural origin, including also identification of new novel compounds.

Acknowledgements

The project was supported by the National Research Foundation of South Africa Grant (111438) awarded to Chipiti T, Enslin G (Grant TK13105723129831), Viljoen AM (86923) and the South African Medical Research Council (Herbal Drugs Research Unit). Clinton Veale gratefully acknowledges financial support in the form of a Future Leaders (FLAIR), research fellowship. The FLAIR Fellowship Programme is a partnership between the African Academy of Sciences and the Royal Society funded by the UK Government’s Global Challenges Research Fund. The African Centre for DNA Barcoding (ACDB), Department of Botany and Plant Biotechnology, University of Johannesburg, South Africa is thanked for performing the genetic studies to confirm species identities.

The authors acknowledge previous and present staff of the Zebrafish Core Facility at the Luxembourg Centre for Systems Biomedicine for their husbandry and technical support for the performance of this study.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jep.2021.114282.

Associated content

Details pertaining to plant collection, identification, DNA barcoding, sample preparation as well as experimental methodologies, and spectral data can be found in the Supplementary Information document.

Author contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. Talent Chipiti collected the plant material, performed the extractions, fractionation and isolation of the compounds in the laboratory of Alvaro M. Viljoen under his guidance and that of Gill M. Ensln, Talent Chipiti conducted the in vivo studies toxicity and bioactivity studies under the guidance of Maria Cordero-Maldonado and Alexander D Crawford, Clinton G. Veale and Fanie R. van Heerden conducted the NMR analysis and interpretation of spectra for identification of isolated compounds, Weiyang Chen and Maxlene Sandasi conducted the chromatographic analysis and assisted with interpretation of chromatographic data. Gill M Ensln coordinated the study and the compilation of the manuscript. Alvaro M Viljoen was responsible for the conceptualization of the project.

References

Afrikanova, T., Serruya, A.S.K., Buenafe, O.E.M., Clinkers, R., Smolders, I., De Witte, P.A.M., Crawford, Esguerra, C.V., 2013. Validation of the zebrafish pentylenetetrazol seizure model: locomotor versus electrographic responses to antiepileptic drugs. PLoS One 8 (1), 1–9.
Auditeau, E., Chassagne, F., Bourdy, G., Bounla, M., Jott, J., Luna, J., Ratsimbazafy, V., Preox, P.M., Boumediene, F., 2019. Herbal medicine for epilepsy seizures in asia, Africa and Latin America: a systematic review. J. Ethnopharmacol. 234, 119–153.
Bello, M.O., Jagaba, S.M., Bello, O.E., 2019. A wild edible vegetable Anchomone diphormis (Blume) Engl: its ethnomedical, phytochemistry, nutritional importance and other uses. EurAsia J. BioSci. 13, 1137–1147.
Berghmans, S., Hunt, J., Roach, A., Goldsmith, P., 2007. Zebrafish offer the potential for a primary screen to identify a wide variety of potential anticonvulsants. Epilepsy Res. 75 (1), 18–28.
Bienvenu, E., Amanbougo, G.J., Eagles, P.K., Scott, G., Springfield, E.P., 2002. Anticonvulsant activity of aqueous extract of Leonurus leonurus. Phytomedicine: International journal of phytotherapy and phycnoparmacology 9 (3), 217–225.
Bosch, C.H., 2008. Bersama abyssinica freens. In: Schmelzer, G.H., Gurb-Fakim, A. (Eds.), PROTA (Plant Resources of Tropical Africa/Resourtes vegetales de l’Afrique tropicale). Wageningen, Netherlands. (Accessed 18 May 2020).
Boikandou Mouanga, M., Mewono, L., Abouge Angone, S., 2015. Toxicity studies of medicinal plants used in sub-Saharan Africa. J. Ethnopharmacol. 174, 618–627.
Brendler, T., Eloff, J.N., Gurb-Fakim, A., Phillips, L.D., 2010. African Herbal Pharmacopoeia, eighteenth ed. Association for African Medicinal Plants Standards, Baie du Tombeau, Mauritius. Graphic Press. Burkhill, H.M., 1985. The Useful Plants of West Tropical Africa, 1. CBRA, 2010. Why are animals necessary in biomedical Research ? www.ca.biomed.org. Challal, S., Buenafe, O.E., Quintero, E.F., Maljevic, S., Marcourt, L., Bock, M., Kloeti, W., Dayrit, F.M., Harvey, A.I., Lerche, H., Esguerra, C.V., de Witte, P.A., Woldfender, J.L., Crawford, A.D., 2014. Zebrafish bioassay-guided microfractionation identifies anticonvulsant steroid glycosides from the Philippines medicinal plant Solanum torvum. ACS Chem. Neurosci. 5, 993–1004.
Crawford, A.D., Esguerra, C.V., de Witte, P.A., 2008. Fishing for drugs from nature: zebrafish as a technology platform for natural product discovery. Planta Med. 74, 624–632.
Cunha, V.T., 2016. Building a zebrafish toolkit for investigating the pathobiology of epilepsy and identifying new treatments for epileptic seizures. J. Neurosci. Methods 260, 91–95.
Cunha, V.T., Baines, R.A., Giachello, C.N.G., Lin, W.H., Morgan, A., Reuber, M., Russell, C., Walker, M.G., Williams, R.S.B., 2015. Epilepsy research methods update: understanding the causes of epileptic seizures and identifying new treatments using non-mammalian model organisms. Seizure 24, 44–51.
Ferreira-Machado, S.C., Rodrigues, M.P., Nunes, A.P., Dantas, F.J., De Mattos, J.C., Silva, C.R., Moura, E.G., Bezerra, R.J., Caldeira-de-Araujo, A., 2004. Genotoxic...
potentiality of aqueous extract prepared from *Chrysobalanus icaco* L. leaves. Toxicol. Lett. 151 (3), 481–487.

Fricke-Galindo, I., Jung-Cook, H., Llerena, A., López-López, M., 2018. Pharmacogenetics of adverse reactions to antiepileptic drugs. Neurol. English Ed. 33, 165–176.

Gad, S.C., 2014. Maximum tolerated dose. Encyclopedia of Toxicology 164.

Galstyan, D.S., Zabegalov, K.N., Tatyana, O., Amstislavskaya, T.G., Strekalova, T., Petersen, E.V., Kalueff, A.V., 2021. Unconventional anxiety pharmacology in zebrafish: drugs beyond traditional anxiogenic and anxiolytic spectra. J Pharm. Biochem.Behavior 173205.

Gao, Y., Zhou, D.S., Kong, L.M., Hai, P., Li, Y., Wang, F., Liu, J.K., 2012. Anticonvulsant activity of *Rauvolfia verticillata* Annonaceae. J. Asian Nat. Prod. Res. 14, 721–726.

Gao, Y., Zhou, D.S., Kong, L.M., Hai, P., Li, Y., Wang, F., Liu, J.K., 2012. Anticonvulsant activity of *Rauvolfia verticillata* Annonaceae. J. Asian Nat. Prod. Res. 14, 721–726.

Gao, Y., Zhou, D.S., Kong, L.M., Hai, P., Li, Y., Wang, F., Liu, J.K., 2012. Anticonvulsant activity of *Rauvolfia verticillata* Annonaceae. J. Asian Nat. Prod. Res. 14, 721–726.

Gao, Y., Zhou, D.S., Kong, L.M., Hai, P., Li, Y., Wang, F., Liu, J.K., 2012. Anticonvulsant activity of *Rauvolfia verticillata* Annonaceae. J. Asian Nat. Prod. Res. 14, 721–726.

Galstyan, D.S., Zabegalov, K.N., Tatyana, O., Amstislavskaya, T.G., Strekalova, T., Petersen, E.V., Kalueff, A.V., 2021. Unconventional anxiety pharmacology in zebrafish: drugs beyond traditional anxiogenic and anxiolytic spectra. J Pharm. Biochem.Behavior 173205.

Gao, Y., Zhou, D.S., Kong, L.M., Hai, P., Li, Y., Wang, F., Liu, J.K., 2012. Anticonvulsant activity of *Rauvolfia verticillata* Annonaceae. J. Asian Nat. Prod. Res. 14, 721–726.

Gao, Y., Zhou, D.S., Kong, L.M., Hai, P., Li, Y., Wang, F., Liu, J.K., 2012. Anticonvulsant activity of *Rauvolfia verticillata* Annonaceae. J. Asian Nat. Prod. Res. 14, 721–726.

Gao, Y., Zhou, D.S., Kong, L.M., Hai, P., Li, Y., Wang, F., Liu, J.K., 2012. Anticonvulsant activity of *Rauvolfia verticillata* Annonaceae. J. Asian Nat. Prod. Res. 14, 721–726.

Gao, Y., Zhou, D.S., Kong, L.M., Hai, P., Li, Y., Wang, F., Liu, J.K., 2012. Anticonvulsant activity of *Rauvolfia verticillata* Annonaceae. J. Asian Nat. Prod. Res. 14, 721–726.

Gao, Y., Zhou, D.S., Kong, L.M., Hai, P., Li, Y., Wang, F., Liu, J.K., 2012. Anticonvulsant activity of *Rauvolfia verticillata* Annonaceae. J. Asian Nat. Prod. Res. 14, 721–726.

Gao, Y., Zhou, D.S., Kong, L.M., Hai, P., Li, Y., Wang, F., Liu, J.K., 2012. Anticonvulsant activity of *Rauvolfia verticillata* Annonaceae. J. Asian Nat. Prod. Res. 14, 721–726.

Gao, Y., Zhou, D.S., Kong, L.M., Hai, P., Li, Y., Wang, F., Liu, J.K., 2012. Anticonvulsant activity of *Rauvolfia verticillata* Annonaceae. J. Asian Nat. Prod. Res. 14, 721–726.

Gao, Y., Zhou, D.S., Kong, L.M., Hai, P., Li, Y., Wang, F., Liu, J.K., 2012. Anticonvulsant activity of *Rauvolfia verticillata* Annonaceae. J. Asian Nat. Prod. Res. 14, 721–726.

Gao, Y., Zhou, D.S., Kong, L.M., Hai, P., Li, Y., Wang, F., Liu, J.K., 2012. Anticonvulsant activity of *Rauvolfia verticillata* Annonaceae. J. Asian Nat. Prod. Res. 14, 721–726.

Gao, Y., Zhou, D.S., Kong, L.M., Hai, P., Li, Y., Wang, F., Liu, J.K., 2012. Anticonvulsant activity of *Rauvolfia verticillata* Annonaceae. J. Asian Nat. Prod. Res. 14, 721–726.

Gao, Y., Zhou, D.S., Kong, L.M., Hai, P., Li, Y., Wang, F., Liu, J.K., 2012. Anticonvulsant activity of *Rauvolfia verticillata* Annonaceae. J. Asian Nat. Prod. Res. 14, 721–726.